Sun Pharmaceuticals Industries, a leading Indian pharma entity with net sales of Rs.27,700 crore plus, has registered strong consolidated net profit growth of 266 per cent during the first quarter ended June 2016 and its net profit went up to Rs.2,034 crore from Rs.556 crore before other comprehensive income. The net profit before exceptional items, minority interest and share of loss of associates and joint ventures improved by 57 per cent to Rs.2,275 crore from Rs.1,445 crore. Its EBDITA increased by 59.3 per cent to Rs.3,078 crore from Rs.1,932 crore. EPS improved to Rs.8.5 from Rs.2.3 in the last period.

The consolidated net sales improved by 22.7 per cent to Rs.8,007 crore from Rs.6,527 crore in the similar quarter of last year. The company's other operating income remained almost same at Rs.236 crore and other income stood at Rs.135 crore. Its employees cost was at Rs.1,239 crore as compared to Rs.1,235 crore in the last period. Depreciation provision amounted to Rs.316 crore as against Rs.240 crore and its finance cost remained almost same at Rs.135 crore. Tax provision went up significantly to Rs.352.71 crore from Rs.112.75 crore.

In the last period the company has provided Rs.685 crore as exceptional items which reduced its profit by the same amount. Other comprehensive income was at Rs.377 crore as compared to Rs.480 crore. .

After the announcement of financial results, Sun Pharma scrip declined by Rs.7.10 and closed at Rs.801.80 with market capitalization of Rs.1,92,969 crore. The scrip touched to its yearly peak level at Rs.965.15 during August 2015 and lowest at Rs.706.40 on November 24, 2015. Its equity capital stood at Rs.240.67 crore.